Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexeo Therapeutics, Inc. - Common Stock (NQ:LXEO)

9.895 +0.265 (+2.75%)
Streaming Delayed Price Updated: 11:19 AM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lexeo Therapeutics, Inc. - Common Stock

News headline image
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor... 
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor... 
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
From Lexeo Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From LEXEO Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
From LEXEO Therapeutics
Via GlobeNewswire
News headline image
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
From LEXEO Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.